Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars

Let the applicant beware!

Misrepresentations are not just limited to examples

by | Jul 8, 2021

Although Australia has taken steps in recent years to harmonise its patent laws with those around the globe, significant differences remain.  This means that patent practitioners operating in one jurisdiction need to have a detailed understanding of the patent laws of any other jurisdictions in which an applicant may seek a patent.

In pursuing protection in the United States, one area in which patent practitioners need to exercise care is the requirement to act in good faith before the United States Patent and Trademark Office (USPTO).  While an Australian practitioner will not directly act before the USPTO, this does not absolve the Australian practitioner of responsibility.  For example, when filing an Australia-originating application, issues relevant to the USPTO’s good faith requirement may arise long before the USPTO becomes involved.  This will primarily involve how the Australian patent practitioner drafts the originating application, and specifically how examples are presented.

The USPTO has reminded applicants in a recent notice that worked examples must be clearly distinguished from examples that have not been carried out (prophetic examples).  Only worked examples are to be presented in the past tense.  Thus, patent practitioners in jurisdictions outside the United States need to carefully present prophetic examples in patent applications in the present tense.  All of the examples should be presented in a manner such that the skilled reader can distinguish between what has and has not been carried out.  Failures to clearly distinguish between worked and prophetic examples have rendered granted United States patents unenforceable.  Thus, patent practitioners outside the United States drafting applications need to carefully draft examples with this requirement in mind.

Patent practitioners also need to be aware of Australia’s related requirements.  In Australia, a patent may be revoked on the ground of “fraud, false suggestion or misrepresentation”.  Even statements made in good faith may engage this ground; an incorrect statement made by or on behalf of the patentee can constitute false suggestion or a misrepresentation (but not fraud) even if the patentee believes it to be true.  The applicable test is whether the false suggestion or misrepresentation materially contributed to the examiner’s decision to grant the patent.

Similar to the United States, false suggestions or misrepresentations can include statements in the examples that imply an experiment has been performed when it has not, as well as suggestions or misrepresentations in statements made elsewhere in the description.  Patents have been revoked in Australia where the problem said to have been solved did not in fact exist, and where an assertion made by the patentee selectively relied on results recorded in the examples but ignored the results of the patentee’s other experiments.  Further, like the United States, false suggestions or misrepresentations can include statements made to the examiner during prosecution of the patent.  Thus, those drafting patent applications for eventual protection in Australia need to carefully consider the whole of the specification to ensure compliance with Australia’s good faith requirements.

 

 

Naomi Pearce

Naomi Pearce

CEO, Executive Lawyer, Patent & Trade Mark Attorney

Naomi is the founder of Pearce IP, and is one of Australia’s leading IP practitioners.  Ranked in virtually every notable legal directory, highly regarded by peers and clients, with a background in molecular biology, Naomi is market leading in the field of pharma/biopharma, biotechnology and animal health.   

Underpinning Naomi’s legal work is a deep understanding of pharma/biopharma industries, resulting from 25+ years' experience, including as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm and as the Founding Principal of Pearce IP.

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News